Laboratorios Farmaceuticos Rovi Reports First Quarter 2025 Earnings

Simply Wall St · 6d ago

Laboratorios Farmaceuticos Rovi (BME:ROVI) First Quarter 2025 Results

Key Financial Results

  • Revenue: €154.9m (up 2.5% from 1Q 2024).
  • Net income: €18.1m (up 21% from 1Q 2024).
  • Profit margin: 12% (up from 9.9% in 1Q 2024).
  • EPS: €0.35.
earnings-and-revenue-growth
BME:ROVI Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Laboratorios Farmaceuticos Rovi Earnings Insights

Looking ahead, revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in Spain.

Performance of the Spanish Pharmaceuticals industry.

The company's shares are up 1.3% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Laboratorios Farmaceuticos Rovi's balance sheet and an in-depth analysis of the company's financial position.